New hope for Tough-to-Treat lymphoma: adding a pill to standard chemo
NCT ID NCT04002947
Summary
This study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers will first give participants the pill alone for two weeks to see if their tumors shrink, then combine it with chemotherapy if it shows promise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.